Related references
Note: Only part of the references are listed.Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver
Won-il Jeong et al.
CELL METABOLISM (2008)
Advances in male contraception
Stephanie T. Page et al.
ENDOCRINE REVIEWS (2008)
Daily cannabis use: A novel risk factor of steatosis severity in patients with chronic hepatitis C
Christophe Hezode et al.
GASTROENTEROLOGY (2008)
Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice
Douglas Osei-Hyiaman et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms
Christoph Buettner et al.
NATURE MEDICINE (2008)
Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet β-cells via CB1 receptors
Masanori Nakata et al.
REGULATORY PEPTIDES (2008)
The orphan receptor GPR55 is a novel cannabinoid receptor
E. Ryberg et al.
BRITISH JOURNAL OF PHARMACOLOGY (2007)
The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms
Claudio Pagano et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species
Soeren V. Siegmund et al.
FASEB JOURNAL (2007)
Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity
K. Kempf et al.
HORMONE AND METABOLIC RESEARCH (2007)
Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome
Lydia E. Kuo et al.
NATURE MEDICINE (2007)
Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
Magali Gary-Bobo et al.
HEPATOLOGY (2007)
The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food
Tiziana Melis et al.
NEUROSCIENCE LETTERS (2007)
Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat
Harini Sampath et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Obesity induces a phenotypic switch in adipose tissue macrophage polarization
Carey N. Lumeng et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Biochemistry and pharmacology of endovanilloids
Katarzyna Starowicz et al.
PHARMACOLOGY & THERAPEUTICS (2007)
Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB1 and VR1 receptors
L. Moezi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Andre J. Scheen et al.
LANCET (2006)
Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma
Xundi Xu et al.
CANCER GENETICS AND CYTOGENETICS (2006)
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity
Matthias Blueher et al.
DIABETES (2006)
Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia
Isabel Matias et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis
Fatima Teixeira-Clerc et al.
NATURE MEDICINE (2006)
MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity
Hajime Kanda et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial
F Pi-Sunyer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
The endocannabinoid system as an emerging target of pharmacotherapy
Pal Pacher et al.
PHARMACOLOGICAL REVIEWS (2006)
Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit
YH Jo et al.
NEURON (2005)
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
JP Despres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activation of the peripheral endocannabinoid system in human obesity
S Engeli et al.
DIABETES (2005)
The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance
O Jbilo et al.
FASEB JOURNAL (2005)
Effects of diet and genetic background on sterol regulatory element-binding protein-1c, stearoyl-CoA desaturase 1, and the development of the metabolic syndrome
SB Biddinger et al.
DIABETES (2005)
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity
D Osei-Hyiaman et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
LF Van Gaal et al.
LANCET (2005)
Antifibrogenic role of the cannabinoid receptor CB2 in the liver
B Julien et al.
GASTROENTEROLOGY (2005)
Structure and function of fatty acid amide hydrolase
MK McKinney et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2005)
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice
YL Liu et al.
INTERNATIONAL JOURNAL OF OBESITY (2005)
Hyperlipidemic effects of dietary saturated fats mediated through PGC-1β cactivation of SREBP
JD Lin et al.
CELL (2005)
The anti-obesity effect of rimonabant is associated with an improved serum lipid profile
B Poirier et al.
DIABETES OBESITY & METABOLISM (2005)
CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity
CR Trillou et al.
INTERNATIONAL JOURNAL OF OBESITY (2004)
Vasodilator mRNA levels are increased in the livers of portal hypertensive NO-synthase 3-deficient mice
E Biecker et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2004)
Cannabinoid agonist, CP 55,940, facilitates intake of palatable foods when injected into the hindbrain
CC Miller et al.
PHYSIOLOGY & BEHAVIOR (2004)
Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-κB independently of platelet-activating factor
J Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis
D Cota et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Preferential effects of the cannabinoid CB, receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats
SP Vickers et al.
PSYCHOPHARMACOLOGY (2003)
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells
M Bensaid et al.
MOLECULAR PHARMACOLOGY (2003)
Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance
HY Xu et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Minireview: Nutrient sensing and the regulation of insulin action and energy balance
S Obici et al.
ENDOCRINOLOGY (2003)
Brain monoglyceride lipase participating in endocannabinoid inactivation
TP Dinh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss
P Cohen et al.
SCIENCE (2002)
Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats
N Jamshidi et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells
EV Berdyshev et al.
FASEB JOURNAL (2001)
Leptin-regulated endocannabinoids are involved in maintaining food intake
V Di Marzo et al.
NATURE (2001)
Share Paper
